The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study is designed to evaluate different starting dose strategies for two FDA-approved CDK4/6 inhibitors in older adults with metastatic, hormone receptor–positive, HER2-negative breast cancer. The study seeks to learn whether starting treatment at a lower dose and increasing as tolerated may help patients remain on therapy longer with fewer side effects, compared to starting at the full standard dose.
The CDK Study is now enrolling patients at the following locations as part of MCGI:
The CDK Study is now enrolling and is available at cancer centers and clinics across the United States. For more details, talk to your oncologist or visit www.cdkstudy.org.